<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000317</url>
  </required_header>
  <id_info>
    <org_study_id>#3124</org_study_id>
    <secondary_id>R01DA009582</secondary_id>
    <nct_id>NCT00000317</nct_id>
    <nct_alias>NCT00000272</nct_alias>
  </id_info>
  <brief_title>Early Phase II Trials for Cocaine Medication Development - 1</brief_title>
  <official_title>Early Phase II Trials for Cocaine Medication Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop models for early Phase II testing of potential&#xD;
      medications for cocaine dependence: amoxapine, risperidone and other agents.&#xD;
&#xD;
      The study was a controlled pilot trial of risperidone in opiate-dependent patients on&#xD;
      methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine&#xD;
      craving, and cocaine subjective effects in patients on methadone maintenance who abused&#xD;
      cocaine and whether it had an acceptable side effect profile. This&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an 18-week prospective, randomized, placebo-controlled crossover design with placebo&#xD;
      lead-in phase and terminal placebo phase. After two weeks of single-blind placebo, patients&#xD;
      were randomly assigned to one of two schedules of medication:&#xD;
&#xD;
      2 Week Baseline Weeks 1-6 Weeks 7-12 Weeks 13-18 Group 1 placebo risperidone placebo placebo&#xD;
      Group 2 placebo placebo risperidone placebo&#xD;
&#xD;
      The first 6-week phase provided an initial double-blind medication-placebo comparison. In the&#xD;
      second six-week phase (weeks 7-12), patients crossed over to the opposite treatment. During&#xD;
      weeks 13-18, Group 1 patients remained on placebo while Group 2 patients were tapered from&#xD;
      risperidone to placebo. For six weeks after the end of the trial, patients were offered&#xD;
      routine clinical treatment with counseling and psychiatrist visits as needed. Medication&#xD;
      dosage was titrated upwards on a fixed-flexible schedule to a maximum dose of 4 mg per day.&#xD;
      Medication began at Â½ mg risperidone for 3 days, then 1 mg for four days, 2 mg per day during&#xD;
      week 2, 3 mg per day during week 3, and 4 mg per day during weeks 4-6. The titration schedule&#xD;
      for risperidone in weeks 7-12 was the same as for weeks 1-6. In addition to treatment as&#xD;
      usual, patients received a modified manual-guided relapse prevention counseling program in&#xD;
      weekly meetings lasting approximately 20 minutes; these sessions provided cognitive and&#xD;
      behavioral skills that were found to be helpful to patients in reducing cocaine use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1996</start_date>
  <completion_date type="Actual">July 1999</completion_date>
  <primary_completion_date type="Actual">July 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Side effects</measure>
    <time_frame>1x/week for 18 weeks</time_frame>
    <description>Using the Modified Systemic Assessment for Treatment Emergent Effects the psychiatrist assessed side effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Craving</measure>
    <time_frame>3x/week during 18 weeks of trial</time_frame>
    <description>subjective cravings were recorded on the Cocaine craving scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug use</measure>
    <time_frame>3x/week during 18 weeks of trial</time_frame>
    <description>urine drug testing and self reported use on the Substance Use Weekly Inventory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention</measure>
    <time_frame>18 weeks or length of study participation</time_frame>
    <description>duration of individuals in the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>PLacebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus relapse prevention counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone (4mg/day) plus relapse prevention counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone (4mg/day)</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>Risperidal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>PLacebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relapse prevention counseling</intervention_name>
    <description>Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.</description>
    <arm_group_label>PLacebo</arm_group_label>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>RPT-CBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. good standing at methadone maintenance program&#xD;
&#xD;
          2. DSM-IV criteria for cocaine dependence or abuse&#xD;
&#xD;
          3. used cocaine at least 4 times in last month&#xD;
&#xD;
          4. able to give informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. currently meets DSM-IV criteria for Major depression or dysthymia&#xD;
&#xD;
          2. meets DSM-IV criteria for attention deficit hyperactivity disorder, bipolar disorder,&#xD;
             schizophrenia or any psychotic disorder&#xD;
&#xD;
          3. history of seizures&#xD;
&#xD;
          4. history of allergic reaction to risperidone&#xD;
&#xD;
          5. chronic organic mental disorder&#xD;
&#xD;
          6. significant current suicidal risk&#xD;
&#xD;
          7. pregnancy, lactation or failure to use adequate birth control (for females)&#xD;
&#xD;
          8. unstable physical disorders that may make participation hazardous&#xD;
&#xD;
          9. coronary vascular disease&#xD;
&#xD;
         10. cardiac conduction system disease as indicated by QRS duration &gt;/= 0.11&#xD;
&#xD;
         11. current use of other prescribed psychotropic medications&#xD;
&#xD;
         12. history of failure to respond to a previous adequate trial of risperidone&#xD;
&#xD;
         13. history of neuroleptic malignant syndrome, tardive dyskinesia, or severe&#xD;
             extrapyramidal reactions to neuroleptic medications&#xD;
&#xD;
         14. current DSM-IV criteria for another substance dependence other than nicotine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Nunes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYS Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYS Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>September 20, 1999</study_first_submitted>
  <study_first_submitted_qc>September 20, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 1999</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>METHADONE PATIENTS</keyword>
  <keyword>RISPERIDONE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

